A secondary goal of this is to investigate BAFF levels in a subset of juvenile myositis (JM) patients with and without ILD compared to matched controls to determine whether BAFF levels correlate with the presence of ILD in JM and to determine if BAFF may also serve as a biomarker for general JM disease activity. This evidence concerns the gene TNFSF13B and juvenile dermatomyositis.